Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of sequential docetaxel plus intermittent erlotinib versus erlotinib alone in previously treated advanced non-small cell lung cancer
2008-007644-34Phase 2Active
- Sponsor
- ATHOM
- Start
- Dec 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sequential docetaxel plus intermittent erlotinib with Erlotinib (2 arms). Primary endpoint: Progression-free at 6 months. Started Dec 2008; status: active.
02
Drugs
docetaxelerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-007644-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007644-34.